ReviewFrontiers in immunology2022

Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy.

Mao Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.